DE69821498D1 - Verwendung von amifostin - Google Patents

Verwendung von amifostin

Info

Publication number
DE69821498D1
DE69821498D1 DE69821498T DE69821498T DE69821498D1 DE 69821498 D1 DE69821498 D1 DE 69821498D1 DE 69821498 T DE69821498 T DE 69821498T DE 69821498 T DE69821498 T DE 69821498T DE 69821498 D1 DE69821498 D1 DE 69821498D1
Authority
DE
Germany
Prior art keywords
compounds
aminoalkyl
amifostin
adverse
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69821498T
Other languages
English (en)
Other versions
DE69821498T2 (de
Inventor
Martin Stogniew
S Schein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Application granted granted Critical
Publication of DE69821498D1 publication Critical patent/DE69821498D1/de
Publication of DE69821498T2 publication Critical patent/DE69821498T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Insulating Materials (AREA)
DE69821498T 1997-02-12 1998-02-11 Verwendung von amifostin Expired - Lifetime DE69821498T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US798840 1997-02-12
US08/798,840 US6051563A (en) 1997-02-12 1997-02-12 Methods for the administration of amifostine and related compounds
PCT/US1998/003614 WO1998034622A1 (en) 1997-02-12 1998-02-11 Methods for the administration of amifostine

Publications (2)

Publication Number Publication Date
DE69821498D1 true DE69821498D1 (de) 2004-03-11
DE69821498T2 DE69821498T2 (de) 2004-12-02

Family

ID=25174410

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69821498T Expired - Lifetime DE69821498T2 (de) 1997-02-12 1998-02-11 Verwendung von amifostin

Country Status (11)

Country Link
US (3) US6051563A (de)
EP (1) EP1007055B1 (de)
JP (1) JP2001512447A (de)
AT (1) ATE258797T1 (de)
AU (1) AU750591B2 (de)
CA (2) CA2625727A1 (de)
DE (1) DE69821498T2 (de)
DK (1) DK1007055T3 (de)
ES (1) ES2216271T3 (de)
PT (1) PT1007055E (de)
WO (1) WO1998034622A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US6573253B2 (en) 1997-02-12 2003-06-03 Medimmune Oncology Inc. Methods for the administration of amifostine and related compounds
US6051563A (en) * 1997-02-12 2000-04-18 U.S. Bioscience, Inc. Methods for the administration of amifostine and related compounds
US5994409A (en) * 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
US6239119B1 (en) * 1998-04-27 2001-05-29 Medimmune Oncology, Inc. Topical administration of amifostine and related compounds
US6384259B1 (en) * 1998-11-16 2002-05-07 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and dosage form
US6407278B2 (en) 1998-11-16 2002-06-18 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and methods for the preparation and use of the same
KR20030014208A (ko) 2000-04-26 2003-02-15 오레곤 헬스 사이언시즈 유니버시티 티올계 화학보호제 화합물의 투여
US7053072B2 (en) * 2001-05-11 2006-05-30 Medimmune Oncology, Inc. Methods for the administration of amifostine and related compounds
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
DE60309300T3 (de) * 2002-03-20 2011-02-24 Elan Pharma International Ltd. Nanopartikelzusammensetzungen von angiogeneseinhibitoren
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US7629333B2 (en) 2002-03-29 2009-12-08 Medimmune, Llc Stable amorphous amifostine compositions and methods for the preparation and use of same
CA2584138A1 (en) * 2004-10-18 2006-04-27 Raphael C. Lee Methods and compositions for treatment of free radical injury
WO2011008885A1 (en) * 2009-07-15 2011-01-20 Portola Pharmaceuticals, Inc. Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same
CN103336902B (zh) * 2013-06-27 2016-01-13 西安交通大学 一种基于模拟分布平衡血药浓度的药物绝对生物利用度检测方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3892824A (en) * 1968-12-16 1975-07-01 Southern Res Inst S-{107 -({107 -aminoalkylamino)alkyl dihydrogen phosphorothioates
WO1989007942A1 (en) * 1988-02-23 1989-09-08 U.S. Bioscience Method for protection from chemotherapeutic side effects
US5424471A (en) * 1992-07-31 1995-06-13 U.S. Bioscience, Inc. Crystalline amifostine compositions and methods of the preparation and use of same
SG47101A1 (en) 1992-07-31 1998-03-20 Us Bioscience Crystalline amifostine compositions and methods for the preparation and use of same
ATE173627T1 (de) * 1992-09-04 1998-12-15 Fuji Chem Ind Co Ltd Medizinische zusammensetzung
DE69526395D1 (de) * 1994-08-13 2002-05-23 Roche Diagnostics Gmbh Verwendung von Interferon-gamma zur Vermeidung der Proliferation und Differenzierung der primitiven Hämapoietischen Vorläuferzellen
US5846958A (en) * 1995-02-17 1998-12-08 U.S. Bioscience, Inc. Methods of using aminothiols to promote hematopoietic progenitor cell growth
US6051563A (en) * 1997-02-12 2000-04-18 U.S. Bioscience, Inc. Methods for the administration of amifostine and related compounds

Also Published As

Publication number Publication date
CA2280773A1 (en) 1998-08-13
PT1007055E (pt) 2004-06-30
US6051563A (en) 2000-04-18
DK1007055T3 (da) 2004-06-07
DE69821498T2 (de) 2004-12-02
US6218377B1 (en) 2001-04-17
AU6184998A (en) 1998-08-26
ATE258797T1 (de) 2004-02-15
US6127351A (en) 2000-10-03
JP2001512447A (ja) 2001-08-21
AU750591B2 (en) 2002-07-25
EP1007055A4 (de) 2002-05-29
CA2280773C (en) 2008-07-22
CA2625727A1 (en) 1998-08-13
WO1998034622A1 (en) 1998-08-13
ES2216271T3 (es) 2004-10-16
EP1007055B1 (de) 2004-02-04
EP1007055A1 (de) 2000-06-14

Similar Documents

Publication Publication Date Title
DE69821498D1 (de) Verwendung von amifostin
HK1245320A1 (zh) 治療缺陷α半乳糖苷酶A的藥物製劑
KR900009079A (ko) 비스(3,5-디-tert-부틸-4-히드록시페닐티오)메탄 함유 콜레스테롤 저하제겸 아테롬성 동맥 경화증 치료제
ATE246197T1 (de) Neue heteroaromatische fructose 1,6- bisphosphatase inhibitoren
BR9809425A (pt) Conjugados alfa interferon-polietilenoglicol para terapia de infecção
NZ516349A (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
MX9603925A (es) Combinaciones de anticoagulantes y proteinas activas tromboliticamente, y usos de las mismas.
ATE239474T1 (de) Verwendung von levobupivacain
MY125984A (en) Pharmaceutical solutions of levosimendan.
DE69617729D1 (de) Verwendung von antimineralcorticoidverbindungen gegen das drogenentzugssyndrom
MXPA02010316A (es) Terapia novedosa para los trastornos asociados con la hiperlipidemia.
ATE372774T1 (de) Medikament zur verabreichung von amifostin und verwandten wirkstoffen
TR200001288T2 (tr) Östrojen yoksunluğu sendromunun tedavisinde faydalı 2-arilbenzo (b) tiyofenler.
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
RS52011B (sr) Nova primena derivata taksoida
DE69808440T2 (de) Verwendung von (+)mefloquine zur behandlung von malaria
DE69018099D1 (de) Polyamin-Derivate als antineoplastische Mittel.
TR200000728T2 (tr) Kronik hepatit C&#39; nin tedavisinde IFN-alfa ve amantadin kullanımı.
SE9003181D0 (sv) Use of heparin fraction
AU2444695A (en) Use of intravenously administered iron in the therapy of tumoral and infectious diseases
IT9048106A0 (it) Associazione medicamentosa per il trattamento dell&#39;ipertensione e dell&#39;insufficienza cardiaca congestiva. (caso 100-7516)
UA29943A (uk) Спосіб лікування хворих на хронічний гепатит
UA29106A (uk) Спосіб лікування вібраційної хвороби
DE59809592D1 (de) Verwendung von putamen ovi

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: MEDIMMUNE ONCOLOGY, INC., GAITHERSBURG, MD., US